This clinical trial is focused on studying the long-term effects of a treatment called Zanubrutinib, also known by its code name BGB-3111. The study is specifically for patients with a type of blood cancer known as B-cell malignancies, which affects the lymph nodes. The purpose of the study is to evaluate the long-term safety of Zanubrutinib regimens in patients who have previously participated in a related study sponsored by the company BeiGene.

Participants in this study will continue to receive Zanubrutinib in the form of capsules taken orally. The study is open-label, meaning both the researchers and participants know what treatment is being administered. The study will take place over an extended period, allowing researchers to gather information on the safety and effects of the treatment over time. Some participants may receive a placebo as part of the study design.

The main focus of the study is to monitor the safety of the treatment by observing any side effects or adverse events that occur. Additionally, researchers will assess how long patients remain free from disease progression, the duration of their response to the treatment, and their overall survival. This information will help determine the long-term benefits and risks of using Zanubrutinib for treating B-cell malignancies.